• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

干细胞技术在心脏再生中的应用:多能干细胞的承诺。

Stem Cell Technology in Cardiac Regeneration: A Pluripotent Stem Cell Promise.

机构信息

Translational Cardiomyology Laboratory, Stem Cell Institute Leuven, Stem Cell Biology and Embryology Unit, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium.

Translational Cardiomyology Laboratory, Stem Cell Institute Leuven, Stem Cell Biology and Embryology Unit, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium; Division of Human Anatomy, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy.

出版信息

EBioMedicine. 2017 Feb;16:30-40. doi: 10.1016/j.ebiom.2017.01.029. Epub 2017 Jan 27.

DOI:10.1016/j.ebiom.2017.01.029
PMID:28169191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5474503/
Abstract

Despite advances in cardiovascular biology and medical therapy, heart disorders are the leading cause of death worldwide. Cell-based regenerative therapies become a promising treatment for patients affected by heart failure, but also underline the need for reproducible results in preclinical and clinical studies for safety and efficacy. Enthusiasm has been tempered by poor engraftment, survival and differentiation of the injected adult stem cells. The crucial challenge is identification and selection of the most suitable stem cell type for cardiac regenerative medicine. Human pluripotent stem cells (PSCs) have emerged as attractive cell source to obtain cardiomyocytes (CMs), with potential applications, including drug discovery and toxicity screening, disease modelling and innovative cell therapies. Lessons from embryology offered important insights into the development of stem cell-derived CMs. However, the generation of a CM population, uniform in cardiac subtype, adult maturation and functional properties, is highly recommended. Moreover, hurdles regarding tumorigenesis, graft cell death, immune rejection and arrhythmogenesis need to be overcome in clinical practice. Here we highlight the recent progression in PSC technologies for the regeneration of injured heart. We review novel strategies that might overcome current obstacles in heart regenerative medicine, aiming at improving cell survival and functional integration after cell transplantation.

摘要

尽管心血管生物学和医学治疗取得了进展,但心脏疾病仍是全球范围内的主要死亡原因。基于细胞的再生疗法成为心力衰竭患者的一种有前途的治疗方法,但也强调了在临床前和临床研究中需要可重复的结果,以确保安全性和有效性。由于注入的成年干细胞的植入、存活和分化效果不佳,人们的热情有所减退。关键的挑战是确定和选择最适合心脏再生医学的干细胞类型。人类多能干细胞 (PSCs) 已成为获得心肌细胞 (CMs) 的有吸引力的细胞来源,具有包括药物发现和毒性筛选、疾病建模和创新细胞治疗在内的潜在应用。胚胎学的经验教训为干细胞衍生的 CMs 的发展提供了重要的见解。然而,生成在心脏亚型、成人成熟和功能特性方面均匀的 CM 群体是非常必要的。此外,在临床实践中还需要克服致瘤性、移植物细胞死亡、免疫排斥和心律失常等障碍。在这里,我们重点介绍了用于损伤心脏再生的 PSC 技术的最新进展。我们回顾了可能克服心脏再生医学当前障碍的新策略,旨在提高细胞移植后的细胞存活和功能整合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5183/5474503/e37f9c05a59a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5183/5474503/ff5afe484107/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5183/5474503/a23cef378c60/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5183/5474503/e37f9c05a59a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5183/5474503/ff5afe484107/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5183/5474503/a23cef378c60/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5183/5474503/e37f9c05a59a/gr3.jpg

相似文献

1
Stem Cell Technology in Cardiac Regeneration: A Pluripotent Stem Cell Promise.干细胞技术在心脏再生中的应用:多能干细胞的承诺。
EBioMedicine. 2017 Feb;16:30-40. doi: 10.1016/j.ebiom.2017.01.029. Epub 2017 Jan 27.
2
Recent Progress Using Pluripotent Stem Cells for Cardiac Regenerative Therapy.利用多能干细胞进行心脏再生治疗的最新进展
Circ J. 2017 Jun 23;81(7):929-935. doi: 10.1253/circj.CJ-17-0400. Epub 2017 Jun 10.
3
Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair.人类多能干细胞:作为用于体外建模和基于细胞的心脏修复的心肌细胞来源的前景与挑战。
Adv Drug Deliv Rev. 2016 Jan 15;96:3-17. doi: 10.1016/j.addr.2015.05.004. Epub 2015 May 14.
4
A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.一个用于从多能干细胞大规模生产人类心肌细胞的通用且强大的集成平台。
Stem Cells Transl Med. 2015 Dec;4(12):1482-94. doi: 10.5966/sctm.2014-0275. Epub 2015 Oct 28.
5
Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.多能干细胞衍生的心肌细胞作为细胞治疗应用的平台:临床转化的进展和障碍。
Mol Ther. 2018 Jul 5;26(7):1624-1634. doi: 10.1016/j.ymthe.2018.02.026. Epub 2018 Mar 6.
6
Perspective from the heart: the potential of human pluripotent stem cell-derived cardiomyocytes.从心脏角度看:人类多能干细胞衍生的心肌细胞的潜力。
J Cell Biochem. 2013 Jan;114(1):39-46. doi: 10.1002/jcb.24359.
7
Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.心血管再生医学的最新进展对临床治疗和药物发现的影响。
Pharmacol Ther. 2010 May;126(2):109-18. doi: 10.1016/j.pharmthera.2010.01.010. Epub 2010 Feb 13.
8
Human cardiomyocyte generation from pluripotent stem cells: A state-of-art.从多能干细胞生成人类心肌细胞:最新进展。
Life Sci. 2016 Jan 15;145:98-113. doi: 10.1016/j.lfs.2015.12.023. Epub 2015 Dec 10.
9
Cardiomyocytes derived from pluripotent stem cells: progress and prospects from China.多能干细胞衍生的心肌细胞:来自中国的进展和前景。
Exp Cell Res. 2013 Jan 15;319(2):120-5. doi: 10.1016/j.yexcr.2012.09.011. Epub 2012 Sep 25.
10
MicroRNA-mediated maturation of human pluripotent stem cell-derived cardiomyocytes: Towards a better model for cardiotoxicity?微小RNA介导的人多能干细胞衍生心肌细胞的成熟:迈向更好的心脏毒性模型?
Food Chem Toxicol. 2016 Dec;98(Pt A):17-24. doi: 10.1016/j.fct.2016.05.025. Epub 2016 Jun 3.

引用本文的文献

1
Extracellular vesicle therapeutics for cardiac repair.用于心脏修复的细胞外囊泡疗法。
J Mol Cell Cardiol. 2025 Feb;199:12-32. doi: 10.1016/j.yjmcc.2024.11.005. Epub 2024 Nov 26.
2
Fibroblast Reprogramming in Cardiac Repair.心脏修复中的成纤维细胞重编程
JACC Basic Transl Sci. 2023 Sep 20;9(1):145-160. doi: 10.1016/j.jacbts.2023.06.012. eCollection 2024 Jan.
3
Polarizing Macrophage Functional Phenotype to Foster Cardiac Regeneration.极化巨噬细胞功能表型以促进心脏再生。

本文引用的文献

1
Activin A Modulates CRIPTO-1/HNF4 Cells to Guide Cardiac Differentiation from Human Embryonic Stem Cells.激活素A调节CRIPTO-1/HNF4细胞以引导人类胚胎干细胞向心脏分化。
Stem Cells Int. 2017;2017:4651238. doi: 10.1155/2017/4651238. Epub 2017 Jan 9.
2
Generation and purification of human stem cell-derived cardiomyocytes.人干细胞衍生心肌细胞的生成与纯化。
Differentiation. 2016 Apr-Jun;91(4-5):126-38. doi: 10.1016/j.diff.2016.01.001. Epub 2016 Feb 22.
3
Mesodermal iPSC-derived progenitor cells functionally regenerate cardiac and skeletal muscle.
Int J Mol Sci. 2023 Jun 28;24(13):10747. doi: 10.3390/ijms241310747.
4
Mesoangioblasts at 20: From the embryonic aorta to the patient bed.20岁的中胚层血管母细胞:从胚胎主动脉到患者病床
Front Genet. 2023 Jan 4;13:1056114. doi: 10.3389/fgene.2022.1056114. eCollection 2022.
5
Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays.荧光人诱导多能干细胞源性 MYH6-mScarlet 心肌细胞用于实时示踪、成像和心脏毒性检测。
Cell Biol Toxicol. 2023 Feb;39(1):145-163. doi: 10.1007/s10565-022-09742-0. Epub 2022 Jul 23.
6
In vitro atlas of dorsal spinal interneurons reveals Wnt signaling as a critical regulator of progenitor expansion.体外背侧脊髓中间神经元图谱揭示 Wnt 信号作为祖细胞扩增的关键调节因子。
Cell Rep. 2022 Jul 19;40(3):111119. doi: 10.1016/j.celrep.2022.111119.
7
DNA Tension Probes Show that Cardiomyocyte Maturation Is Sensitive to the Piconewton Traction Forces Transmitted by Integrins.DNA 张力探针显示,心肌细胞成熟对整合素传递的皮牛顿牵引力敏感。
ACS Nano. 2022 Apr 26;16(4):5335-5348. doi: 10.1021/acsnano.1c04303. Epub 2022 Mar 24.
8
Recent Advances in Cardiac Tissue Engineering for the Management of Myocardium Infarction.心脏组织工程学在心肌梗死管理中的最新进展。
Cells. 2021 Sep 25;10(10):2538. doi: 10.3390/cells10102538.
9
Cortical bone stem cell-derived exosomes' therapeutic effect on myocardial ischemia-reperfusion and cardiac remodeling.皮质骨干细胞衍生的外泌体对心肌缺血再灌注和心脏重构的治疗作用。
Am J Physiol Heart Circ Physiol. 2021 Dec 1;321(6):H1014-H1029. doi: 10.1152/ajpheart.00197.2021. Epub 2021 Oct 8.
10
Bone-Marrow Stem Cells and Acellular Human Amniotic Membrane in a Rat Model of Heart Failure.骨髓干细胞与脱细胞人羊膜在大鼠心力衰竭模型中的应用
Life (Basel). 2021 Sep 13;11(9):958. doi: 10.3390/life11090958.
中胚层诱导多能干细胞衍生的祖细胞在功能上可使心肌和骨骼肌再生。
J Clin Invest. 2015 Dec;125(12):4463-82. doi: 10.1172/JCI82735. Epub 2015 Nov 16.
4
Current status of pluripotent stem cells: moving the first therapies to the clinic.多能干细胞的现状:将首批疗法推向临床。
Nat Rev Drug Discov. 2015 Oct;14(10):681-92. doi: 10.1038/nrd4738. Epub 2015 Sep 22.
5
Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction.携带 VEGF 的微载体与脂肪组织间充质细胞的联合移植促进了小鼠心肌梗死的修复。
Cardiovasc Res. 2015 Oct 1;108(1):39-49. doi: 10.1093/cvr/cvv197. Epub 2015 Jul 17.
6
Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes.人诱导多能干细胞衍生的心肌细胞:对分子、细胞和功能表型的见解。
Circ Res. 2015 Jun 19;117(1):80-8. doi: 10.1161/CIRCRESAHA.117.305365.
7
Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair.人类多能干细胞:作为用于体外建模和基于细胞的心脏修复的心肌细胞来源的前景与挑战。
Adv Drug Deliv Rev. 2016 Jan 15;96:3-17. doi: 10.1016/j.addr.2015.05.004. Epub 2015 May 14.
8
Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction.胚胎干细胞衍生的外泌体可促进内源性修复机制,并增强心肌梗死后的心脏功能。
Circ Res. 2015 Jun 19;117(1):52-64. doi: 10.1161/CIRCRESAHA.117.305990. Epub 2015 Apr 22.
9
Signaling Pathways and Gene Regulatory Networks in Cardiomyocyte Differentiation.心肌细胞分化中的信号通路与基因调控网络
Tissue Eng Part B Rev. 2015 Aug;21(4):377-92. doi: 10.1089/ten.TEB.2014.0662. Epub 2015 May 11.
10
In vivo activation of a conserved microRNA program induces mammalian heart regeneration.保守微小RNA程序的体内激活诱导哺乳动物心脏再生。
Cell Stem Cell. 2014 Nov 6;15(5):589-604. doi: 10.1016/j.stem.2014.10.003.